Bavarian Nordic A/S  

(Public, CPH:BAVA)   Watch this stock  
Find more results for BAVA
256.00
-2.50 (-0.97%)
May 25 - Close
CPH real-time data - Disclaimer
Currency in DKK
Range 255.00 - 260.50
52 week 215.50 - 368.00
Open 260.00
Vol / Avg. 204,118.00/221,683.00
Mkt cap 7.89B
P/E     -
Div/yield     -
EPS -4.03
Shares 30.84M
Beta     -
Inst. own     -
Aug 17, 2016
Q2 2016 Bavarian Nordic A/S Earnings Call - 2:00PM GMT+2 - Add to calendar
Aug 17, 2016
Q2 2016 Bavarian Nordic A/S Earnings Release Add to calendar
Jun 21, 2016
Bavarian Nordic A/S at Citi European Healthcare Conference Add to calendar
May 13, 2016
Q1 2016 Bavarian Nordic A/S Earnings Call
May 13, 2016
Q1 2016 Bavarian Nordic A/S Earnings Release
Apr 20, 2016
Bavarian Nordic A/S Annual Shareholders Meeting
Mar 17, 2016
Bavarian Nordic A/S at Carnegie Healthcare Seminar
Mar 7, 2016
Bavarian Nordic A/S at Cowen Health Care Conference
Mar 7, 2016
Q4 2015 Bavarian Nordic A/S Earnings Call - Webcast
Mar 7, 2016
Q4 2015 Bavarian Nordic A/S Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -570.76% 5.82%
Operating margin -677.12% 0.15%
EBITD margin - 5.59%
Return on average assets -26.81% 3.07%
Return on average equity -40.43% 4.58%
Employees 418 -
CDP Score - -

Address

Munkegaarde, Hejreskovvej 10A
KVISTGAARD, 3490
Denmark

Website links

Description

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Officers and directors

Gerard WM van Odijk M.D. Independent Chairman of the Board
Age: 59
Paul Chaplin Ph.D. President, Chief Executive Officer
Age: 49
Anders Gersel Pedersen M.D., Ph.D. Independent Deputy Chairman of the Board
Age: 65
Ole Larsen Chief Financial Officer, Executive Vice President
Age: 51
Claus Braestrup M.D. Independent Director
Age: 71
Erik Gregers Hansen Independent Director
Age: 64
Peter Kurstein Independent Director
Age: 60
Frank A. G. M. Verwiel M.D. Independent Director
Age: 54